GS
Therapeutic Areas
DiaSorin Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LIAISON® QuantiFERON® TB-Gold Plus | Tuberculosis infection detection | Approved/Commercial |
| LIAISON® MeMed BV® | Differentiation of bacterial vs. viral infections | Approved/Commercial |
| LIAISON® Calprotectin | Inflammatory Bowel Disease (IBD) diagnosis & monitoring | Approved/Commercial |
| MUREX Anti-HDV | Hepatitis D Virus (HDV) detection | Approved/Commercial |
| LIAISON® XL System | Immunoassay testing platform | Commercial |
| LIAISON® XS System | Immunoassay testing platform | Commercial |
| Luminex xMAP® Technology | Multiplex testing for infectious disease, genetics | Commercial |
Leadership Team at DiaSorin
CR
Carlo Rosa
Chief Executive Officer (CEO)
PP
Piergiorgio Pedron
Chief Financial Officer (CFO)
MB
Marco Baccanti
Head of Corporate Development & Strategy
DB
Daniele Bencini
Chief Operating Officer (COO) - Operations
FR
Francesco Raimondo
Chief Operating Officer (COO) - Commercial
FP
Fabio Perversi
Chief Human Resources Officer (CHRO)
RV
Rosella Visconti
Chief Quality & Regulatory Affairs Officer